4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
US9409892B2 · kind B2 · utility
6Cited by
31References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2013 |
| Grant date | Aug 9, 2016 |
| Priority date | — |
| Expiry date | Mar 8, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.